ATNM
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Actinium Pharmaceuticals announced intellectual property and manufacturing advances for Actimab-A and provided an update on its NYSE American listingAug 17, 2026
- Actinium Pharmaceuticals announced ATNM-400 data showing potent efficacy in triple-negative breast cancer and ability to overcome endocrine and HER2-targeted therapy resistance, presented at San Antonio Breast Cancer SymposiumDec 1, 2025
- Actinium announces superior anti-tumor activity of ATNM-400 in lung cancer compared to leading first, second and third-line approved EGFR mutant therapies and mechanistic synergy with Osimertinib at AACR-NCI-EORTC conferenceOct 27, 2025
- Actinium presents data showing paradigm-changing potential of ATNM-400 in prostate cancer with superior efficacy and improved survival in resistant tumor models versus Pluvicto and ARPI therapy, and enhanced efficacy combined with ARPI therapy at 4th Annual Targeted Radiopharmaceuticals SummitJul 31, 2025